首页 | 本学科首页   官方微博 | 高级检索  
     


Expression of HLA class I and class II antigens in human choriocarcinoma cell lines
Authors:K Yamashita  T Nakamura  T Shimizu  M Katagiri  H Ikeda
Affiliation:1. Department of Obstetrics and Gynecology, Asahikawa Medical College, Asahikawa, 078-11 Japan;2. Department of Pathology II, Asahikawa Medical College, Asahikawa, 078-11 Japan;1. Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran;2. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran;3. Department of Biology, Faculty of Science, Urmia University, Urmia, Iran;4. Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 171 77, Sweden;5. Department of Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran;6. Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran;7. Neurophysiology Research Center, Urmia University of Medical Sciences, Urmia, Iran;8. School of Nutrition and Dietetics, Acadia University, Wolfville, Nova Scotia, Canada;9. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;10. Molecular MedicineResearch Center, Tabriz University of Medical Sciences, Tabriz, Iran;11. Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran;12. Solid Tumor Research Center, Urmia University of Medical Sciences, Urmia, Iran;1. Department of Chemical Sciences, University of Naples, 80126, Naples, Italy;2. Division of Integrative Biosciences and Biotechnology, Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang, 37673, Republic of Korea;3. Task Force on Microbiome Studies, University of Naples Federico II, Naples, Italy;4. Department of Agricultural Sciences, University of Naples, 80055 Portici, Italy;1. Department of Dermatology, University Hospital Essen, Essen, Germany;2. German Cancer Consortium, Heidelberg, Germany;3. University Hospital Schleswig-Holstein, Kiel, Germany;4. Fondazione Istituto Nazionale Tumori, Milan, Italy;5. Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, QLD, Australia;6. Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy;7. Melanoma Oncology Unit, Veneto Oncology Institute-IRCCS, Padova, Italy;8. Royal Marsden NHS Foundation Trust, London, UK;9. Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway;10. Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France;11. The Alfred Hospital, Melbourne, VIC, Australia;12. Institute Gustave Roussy, Paris, France;13. Université de Lille, INSERM U 1189, Lille, France;14. Medical Oncology Department, Centre Eugène Marquis, Rennes, France;15. Northern Centre for Cancer Care, Freeman Hospital and Newcastle University, Newcastle upon Tyne, UK;p. Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer, Israel;q. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel;r. Novartis Healthcare, Hyderabad, India;s. Novartis Pharmaceuticals, East Hanover, NJ, USA;t. Macquarie University, Sydney, NSW, Australia;u. Melanoma Institute Australia, Sydney, NSW, Australia;v. Westmead Hospital, Sydney, NSW, Australia;w. The University of Sydney, Sydney, NSW, Australia;x. University Hospital Zürich Skin Cancer Center, Zürich, Switzerland;y. Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA;z. Royal North Shore Hospital, Sydney, NSW, Australia;11. Mater Hospital, Sydney, NSW, Australia;1. Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India;2. Department of Pharmaceutics, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia;3. Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Minia University, Minia 61519, Egypt;4. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;1. Gynecology and Obstetrics Department, Peking University Third Hospital, Beijing 100191, PR China;2. Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, PR China
Abstract:Eight choriocarcinoma cell lines (6:gestational origin, 2:non-gestational origin) were studied by a radioimmune inhibition test using monoclonal antibodies for the expression of HLA class I and class II antigens. Levels of HLA class I antigens were very slight or nil. On the other hand, no HLA class II antigen was detected in any choriocarcinoma cell lines examined.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号